Search
for
Sort by
Research 31–60 of 71
- Iron Deficiency in Immune-Mediated Inflammatory Skin Diseases: A Missing Link Between Systemic Inflammation, Immunometabolism, and Disease Burden
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations
- Simultaneous Versus Delayed Initiation of Spironolactone and Low‐Dose Oral Minoxidil: Adverse Event Rates in a Retrospective Cohort Study
- When hair dig into the brain, JAKi , may help!
- Semaglutide and the Skin: An Overview of Current Evidence
- The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
- Could Vaccination against COVID-19 Trigger Immune-Mediated Inflammatory Diseases?
- Celiac disease associated with alopecia areata: A multicenter case-control study
- The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
- 76626 Adjunctive Combined Regenerative Technique (CRT) vs Oral Minoxidil Alone for Androgenetic Alopecia: A Six-Month Retrospective Study
- 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations
- Long-Term Particulate Matter Exposure and Risk of Androgenetic Alopecia: A Nationwide Cohort Study
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
- Neurological post‐acute sequelae of SARS‐CoV‐2 infection
- No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
- Low-dose oral minoxidil for androgenetic alopecia is not associated with blood pressure changes in patients also taking other antihypertensive medications: A multi-center cohort study using TriNetX
- Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study
- 0414 Cumulative atopic disease burden is associated with increased risk of alopecia areata: A TriNetX cohort study
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Broad laboratory testing does not show utility for telogen effluvium: a retrospective analysis of 22-million laboratory results using TriNetX
- Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
- LB892 Assessing the risk of alopecia areata development in patients with seasonal and food allergies: a matched population-level analysis
- 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
- 0441 Systemic autoimmune comorbidity in alopecia totalis and universalis compared with patchy alopecia areata: A retrospective cohort study
- 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization